Voyager Therapeutics, Inc. (VYGR) News
Filter VYGR News Items
VYGR News Results
|Loading, please wait...|
VYGR News Highlights
- VYGR's 30 day story count now stands at 8.
- Over the past 20 days, the trend for VYGR's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- GENE, NBIX and AL are the most mentioned tickers in articles about VYGR.
Latest VYGR News From Around the Web
Below are the latest news stories about VOYAGER THERAPEUTICS INC that investors may wish to consider to help them evaluate VYGR as an investment opportunity.
So, what are the best stocks to buy for less than $25 per share?
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into employment agreements with two newly hired employees that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager. The inducement awards were approved
Shares of the gene therapy company Voyager Therapeutics (NASDAQ: VYGR) were down by a little over 18% from their intraweek high as of 11:44 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. Rather, Voyager's shares seem to be reverting to the mean following their enormous run-up earlier this month. As a refresher, the biotech's shares spiked by as much as 76% during the first two weeks of January as a result of the company's lucrative gene therapy deal with Neurocrine Biosciences (NASDAQ: NBIX).
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.
Apexigen (APGN) stock is rocketing higher on Monday following new coverage of the company from an analyst and heavy trading.
Party City (PRTY) stock is in the news Monday as investors prepare for the celebration goods company to file for bankruptcy.
Voyager Therapeutics Inc., the gene therapy startup led by erstwhile Biogen Inc. executive Al Sandrock, has a new deal with a San Diego biotech that's worth up to $4.4 billion.
Neurocrine Biosciences Inc (NASDAQ: NBIX) and Voyager Therapeutics Inc (NASDAQ: VYGR) have formed a new strategic collaboration to advance multiple gene therapies for neurological diseases. Voyager will receive up-front consideration of $175 million, including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in t
MARKET PULSE Shares of Voyager Therapeutics Inc. (VYGR) rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc. (NBIX) to develop and commercialize gene therapies, including one that is being tested as a treatment for Parkinson’s disease.